Clinical development
Clinical development is where data, patient safety, and regulatory responsibility come together. Decisions taken at this stage directly affect trial outcomes, timelines, and the credibility of the sponsor organisation.
Quality in clinical development is not about adding layers of control. It is about maintaining oversight across complexity, ensuring that responsibilities are clear, risks are understood, and data can be trusted — even when trials involve multiple sites, CROs, and service providers.
Why QAlliance
QAlliance brings senior, sponsor‑side experience to clinical development, helping organisations maintain clear oversight as trials become more complex. We focus on proportionate application of GCP principles, so quality supports trial delivery rather than slowing it down. This helps sponsors demonstrate control, respond confidently to inspections, and protect the credibility of their clinical data.
Typical challenges in clinical development
In our experience, quality issues in clinical development rarely result from missing procedures. They more often arise when oversight, judgement, or accountability does not scale with trial complexity.
Typical challenges include:
Unclear sponsor oversight
Responsibilities between sponsor, CROs, sites, and vendors are defined contractually, but not always operationally.
Inconsistent application of GCP principles
Teams interpret requirements differently across studies, regions, or functions.
Risk assessments that exist, but do not guide decisions
Critical‑to‑quality factors are identified, but not actively used to prioritise oversight.
Reactive quality management
Deviations, findings, or protocol issues are addressed individually rather than as system signals.
Inspection readiness driven by events, not routine control
Quality efforts intensify before inspections instead of being embedded into daily trial oversight.
What is expected of a quality responsible
Quality responsibility in clinical development requires sound judgement under uncertainty.
It means being able to:
- decide where intensified oversight is necessary — and where it is not
- maintain sponsor accountability while working through external partners
- balance operational progress with patient safety and data integrity
- explain decisions clearly to auditors, inspectors, and partners
This role is less about enforcing procedures, and more about demonstrating control, awareness, and consistency across the trial portfolio.
A few practical examples
Transitioning from early trials to larger, multi‑site studies
Oversight models need to evolve without disrupting ongoing trial execution.
Working with several CROs, CMOs or specialised vendors
Clarity is required on who oversees what, how issues are escalated, and how performance is monitored.
Preparing for inspections or partner audits
The focus moves from documentation completeness to whether the sponsor can clearly explain how quality is maintained in practice.